How to appeal a Premera Blue Cross spinal muscular atrophy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Premera Blue Cross-specific note: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.

What Premera Blue Cross's policy requires for spinal muscular atrophy

Cited policy: BCBS Combination / Sequential SMA Disease-Modifying Therapy

Single SMA disease-modifying therapy at a time per most plans. Sequential Zolgensma → Spinraza/Evrysdi maintenance requires medical justification: documented sub-optimal response to gene therapy (CHOP-INTEND plateau, slow milestone gain, 2-copy SMN2 high-risk). Specialist letter from neuromuscular MD.

How Premera Blue Cross denies spinal muscular atrophy — and how to counter it

Where Premera Blue Cross pushes back: 1) Combination labeled experimental; 2) Single therapy sufficient; 3) No FDA approval for combination.

Counter-arguments that hold up: Combination/sequential Zolgensma → Spinraza or Evrysdi maintenance is supported by RESTORE registry (Novartis real-world), multiple peer-reviewed case series (Harada 2021; Lee Fay Sansone 2024), Mercuri 2024 consensus reviews, and ASGCT guidance for selected post-gene-therapy plateau or slow responders. Cure SMA real-world data document widespread practice. NOT a label-defying use — gene therapy + SMN2 splicer have distinct mechanisms; SMN2 modulator addresses residual gene therapy under-expression. Submit specific motor-function trajectory, SMN2 copy number, and neuromuscular specialist rationale.

What Premera Blue Cross typically denies for spinal muscular atrophy

Across Premera Blue Cross's commercial and Medicare books, denials cluster around a small number of patterns. For spinal muscular atrophy, expect:

• WA-specific mental health parity violations
• Step therapy via Express Scripts
• Out-of-network reductions
• Specialty drug prior auth

Treatments most often denied in this category

These are the spinal muscular atrophy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Spinraza (nusinersen)
• Evrysdi (risdiplam)
• Zolgensma (onasemnogene)
• Combination/sequential
• Switching therapy
• BiPAP / NIV

How to submit the appeal to Premera Blue Cross

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Premera Blue Cross cited in the denial.
3. File the appeal through Premera Blue Cross's portal (members: https://www.premera.com ; providers: https://www.premera.com/wa/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In WA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Premera Blue Cross's prior-authorization criteria by drug: Premera Blue Cross PA criteria on ApprovalHelp.